<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399203</url>
  </required_header>
  <id_info>
    <org_study_id>2009X41</org_study_id>
    <nct_id>NCT01399203</nct_id>
  </id_info>
  <brief_title>Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention</brief_title>
  <acronym>CONVIN</acronym>
  <official_title>Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hainan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the predictive value of the contrast media volume to creatinine clearance
      (V/CrCl) ratio for the risk of contrast-induced nephropathy (CIN) (i.e., within 48-72 h) and
      to determine a relatively safe V/CrCl cut-off value to avoid CIN in patients following PCI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      contrast media volume to creatinine clearance (V/CrCl) ratios were obtained from consecutive
      consenting patients after unselective PCI. Receiver-operator characteristic (ROC) curves were
      used to identify the optimal sensitivity for the observed range of V/CrCl. The predictive
      value of V/CrCl for the risk of CIN was assessed using multivariate logistic regression.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-Induced Nephropathy</measure>
    <time_frame>48-72 h</time_frame>
    <description>Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl from the baseline within 48-72 h of contrast exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse clinical events</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>percutaneous coronary intervention</arm_group_label>
    <description>The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators reviewed all consecutive patients who were undergoing percutaneous
        coronary intervention
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who agreed to stay in the hospital for 2-3 days after percutaneous coronary
             intervention

          -  provided written informed consent

          -  Creatinine Clearance:15-60ml/min

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  intravascular administration of an contrast medium within the previous seven days

          -  treatment with metformin

          -  aminoglycosides

          -  N-acetylcysteine (NAC)

          -  nonsteroidal anti-inflammatory drugs within the previous 48 h

          -  intake of nephrotoxic drugs within the previous seven days

          -  history of serious reactions to contrast mediums

          -  severe concomitant disease

          -  renal transplantation , or end-stage renal disease necessitating dialysis patients who
             died during percutaneous coronary intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Tan, MD</last_name>
    <phone>86-20-83819161</phone>
    <email>tanning100@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Liu, MD</last_name>
    <phone>86-15920172292</phone>
    <email>liuyongyisheng@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ning Tan</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Tan, MD</last_name>
      <phone>8620-83819161</phone>
      <email>tanning100@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yong Liu, MD</last_name>
      <phone>8615920172292</phone>
      <email>liuyongyisheng@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yong Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiyan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yingling Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianfang Luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuguang Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2011</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ning Tan, MD</name_title>
    <organization>Guangdong Cardiovascular Institute,Guangdong General Hospital</organization>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>contrast medium</keyword>
  <keyword>creatinine clearance</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

